Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018

References

• Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer. 1998;83(8):1664–1678. doi:10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Beroukhim K, Pourang A, Eisen DB. Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol. 2020;82(3):683–689. doi:10.1016/j.jaad.2019.10.024
   PubMed Web of Science ®Google Scholar
• Boyd N, Dancey JE, Gilks CB, et al. Rare cancers: a sea of opportunity. Lancet Oncol. 2016;17(2):e52–e61. doi:10.1016/S1470-2045(15)00386-1
   PubMed Web of Science ®Google Scholar
• Mahendraraj K, Lau C, Lee I, et al. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7516 patients from the Surveillance, Epidemiology, and End Results database (1973–2012). Clin Ophthalmol. 2016;10:2113–2119. doi:10.2147/OPTH.S113623
   PubMedGoogle Scholar
• Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241–257. doi:10.1038/eye.2016.275
   PubMed Web of Science ®Google Scholar
• Derrien AC, Rodrigues M, Eeckhoutte A, et al.. Germline MBD4 mutations and predisposition to uveal melanoma. J Natl Cancer Inst. 2020;113:80–87.
   Google Scholar
• Thomsen H, Chattopadhyay S, Hoffmann P, et al. Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1. Melanoma Res. 2020;30(2):166–172. doi:10.1097/CMR.0000000000000641
   PubMed Web of Science ®Google Scholar
• OMF. Available from: http://www.ocularmelanoma.org/disease.htm. Accessed July 26, 2021.
   Google Scholar
• Culp MB, Benard V, Dowling NF, et al. Ocular melanoma incidence rates and trends in the United States, 2001–2016. Eye (Lond. 2020;35:687–689.
   PubMed Web of Science ®Google Scholar
• Jager MJ.Uveal melanoma. Nat Rev Disease Primers. 2020;6(1):24.
   PubMed Web of Science ®Google Scholar
• Gass JD. Problems in the differential diagnosis of choroidal nevi and malignant melanomas. The XXXIII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1977;83(3):299–323. doi:10.1016/0002-9394(77)90726-7
   PubMed Web of Science ®Google Scholar
• Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–1885. doi:10.1016/j.ophtha.2011.01.040
   PubMed Web of Science ®Google Scholar
• Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–251. doi:10.1016/0039-6257(88)90173-7
   PubMed Web of Science ®Google Scholar
• Margo CE, Mulla Z, Billiris K. Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology. 1998;105(6):1087–1090. doi:10.1016/S0161-6420(98)96012-2
   PubMed Web of Science ®Google Scholar
• Singh AD, De Potter P, Fijal BA, et al. Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology. 1998;105(1):195–198. doi:10.1016/S0161-6420(98)92205-9
   PubMed Web of Science ®Google Scholar
• Aaberg TM, Cook R, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–2460. doi:10.2147/OPTH.S70839
   PubMedGoogle Scholar
• Jha J, Singh MK, Singh L, et al. Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors. Int J Clin Oncol. 2019;24(12):1526–1535. doi:10.1007/s10147-019-01519-6
   PubMed Web of Science ®Google Scholar
• Steeb T, Hayani KM, Förster P, et al. Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument. J Cancer Res Clin Oncol. 2020;146(4):1079–1088. doi:10.1007/s00432-020-03141-w
   PubMed Web of Science ®Google Scholar
• Singh AD. Prognostication of uveal melanoma: a work in progress. JAMA Ophthalmol. 2016;134(7):740–741. doi:10.1001/jamaophthalmol.2016.1070
   PubMed Web of Science ®Google Scholar
• Drabarek W, Yavuzyigitoglu S, Obulkasim A, et al. Multi-modality analysis improves survival prediction in enucleated uveal melanoma patients. Invest Ophthalmol Vis Sci. 2019;60(10):3595–3605. doi:10.1167/iovs.18-24818
   PubMed Web of Science ®Google Scholar
• Sandinha MT, Farquharson MA, McKay IC, et al. Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci. 2005;46(10):3497–3501. doi:10.1167/iovs.05-0613
   PubMed Web of Science ®Google Scholar
• Eskelin S, Pyrhönen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443–1449. doi:10.1016/S0161-6420(00)00182-2
   PubMed Web of Science ®Google Scholar
• Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110(5):956–961. doi:10.1016/S0161-6420(03)00078-2
   PubMed Web of Science ®Google Scholar
• Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4(3):145–151. doi:10.1159/000480640
   PubMed Web of Science ®Google Scholar
• Lane AM, Egan KM, Kim IK, et al. Mortality after diagnosis of small melanocytic lesions of the choroid. Arch Ophthalmol. 2010;128(8):996–1000. doi:10.1001/archophthalmol.2010.166
   PubMedGoogle Scholar
• Ghazawi FM, Darwich R, Le M, et al. Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. Br J Ophthalmol. 2019;103(12):1872–1876.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122(15):2299–2312. doi:10.1002/cncr.29727
   PubMed Web of Science ®Google Scholar
• Group COMS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: v. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–1693.
   PubMedGoogle Scholar
• Souto EB, Zielinska A, Luis M, et al. Uveal melanoma: physiopathology and new in situ-specific therapies. Cancer Chemother Pharmacol. 2019;84(1):15–32. doi:10.1007/s00280-019-03860-z
   PubMed Web of Science ®Google Scholar
• Surriga O, Rajasekhar VK, Ambrosini G, et al. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 2013;12(12):2817–2826. doi:10.1158/1535-7163.MCT-13-0499
   PubMed Web of Science ®Google Scholar
• Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1):e000331. doi:10.1136/jitc-2019-000331
   PubMed Web of Science ®Google Scholar
• Larribère L, Utikal J. Update on GNA alterations in cancer: Implications for uveal melanoma treatmen. Cancers (Basel). 2020;12(6):1524.
   PubMed Web of Science ®Google Scholar
• Rossi E, Pagliara MM, Orteschi D, et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol Immunother. 2019;68(7):1179–1185. doi:10.1007/s00262-019-02352-6
   PubMed Web of Science ®Google Scholar
• Zanella A, Doussot A, Puzenat E, et al. MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted? Melanoma Res. 2020;30(6):606–607. doi:10.1097/CMR.0000000000000677
   PubMed Web of Science ®Google Scholar
• Luke JJ. The newest treatments for uveal melanoma. Clin Adv Hematol Oncol. 2019;17(9):490–493.
   PubMed Web of Science ®Google Scholar
• Dayani PN, Gould JE, Brown DB, et al. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol. 2009;127(5):628–632. doi:10.1001/archophthalmol.2009.45
   PubMedGoogle Scholar
• Straatsma BR. Mortality after deferral of treatment or no treatment for choroidal melanoma. Indian J Ophthalmol. 2018;66(10):1395–1400. doi:10.4103/ijo.IJO_1499_18
   PubMed Web of Science ®Google Scholar
• Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370–1380. doi:10.1093/annonc/mdz176
   PubMed Web of Science ®Google Scholar
• Rodrigues M, de Koning L, Coupland S, et al. So close, yet so far: discrepancies between uveal and other melanomas. a position paper from UM cure 2020. Cancers (Basel). 2019;11(7):1032. doi:10.3390/cancers11071032
   PubMed Web of Science ®Google Scholar